Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation

Figure 7

Cell proliferation is increased in Ras-transformed cell lines with reduced TDAG51 expression. (A) S phase fraction of RasV12S35-expressing (left panel) or RasV12-expressing (right panel) HME16C infected with pLVTHM non-silencing vector control or anti-TDAG51 shRNA 36-1 after 48, 72, 96 or 120 hours growth in ultra-low attachment plates as determined by cell cycle analysis of propidium iodide-stained nuclei. * p < 0.05; **p < 0.01; ***p < 0.001. (B) Incorporation of the nucleoside analogue EdU into cellular DNA measured in RasV12S35-expressing (left panel) or RasV12-expressing (right panel) HME16C infected with pLVTHM non-silencing vector control or anti-TDAG51 shRNA 36-1 after 48, 72, 96 or 120 hours growth in ultra-low attachment plates. Incorporated EdU was quantified by detection of Alexa Fluor 488-labeled EdU in viable single cells by flow cytometry analysis.

Back to article page